References
- Akira K, Taira T, Hasegawa H, et al. (1998). Studies on the stereoselective internal acyl migration of ketoprofen glucuronides using 13C labeling and nuclear magnetic resonance spectroscopy. Drug Metab Dispos 26:457–64.
- Asaki T, Kuwano K, Morrison K, et al. (2015). Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem 58:7128–37.
- Bruderer S, Hurst N, Kaufmann P, et al. (2014). Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology 94:148–56.
- Dubois N, Lapicque F, Maurice MH, et al. (1993). In vitro irreversible binding of ketoprofen glucuronide to plasma proteins. Drug Metab Dispos 21:617–23.
- Gnerre C, Segrestaa J, Seeland S, et al. (2017). The metabolism and drug–drug interaction potential of the selective prostacyclin receptor agonist selexipag. Xenobiotica doi:10.1080/00498254.2017.1357088 [Epub ahead of Print].
- Ichikawa T, Yamada T, Treiber A, et al. (2018). Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys. Xenobiotica 48:186–96.
- Kaufmann P, Hurst N, Astuc B, Dingemanse J. (2017). Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. Eur J Clin Pharmacol 73:151–6.
- Kaufmann P, Niglis S, Bruderer S, et al. (2015). Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol 80:670–7.
- Kaufmann P, Okubo K, Sidharta PN, et al. (2012). Investigation of the absorption, metabolism, and excretion of 14C-selexipag following oral administration to healthy male subjects. Clin Pharmacol Ther 91(Suppl. 1):S85.
- Kretz-Rommel A, Boelsterli UA. (1994). Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct. Drug Metab Dispos 22:956–61.
- Kuwano K, Hashino A, Asaki T, et al. (2007). 2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 322:1181–8.
- Li B, Sedlacek M, Manoharan I, et al. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84.
- Nakamura A, Yamada T, Asaki T. (2007). Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist. Bioorg Med Chem 15:7720–5.
- Presle N, Lapicque F, Fournel-Gigleux S, et al. (1996). Stereoselective irreversible binding of ketoprofen glucuronides to albumin. Characterization of the site and the mechanism. Drug Metab Dispos 24:1050–7.
- Scott LJ. (2016). Selexipag: first global approval. Drugs 76:413–8.
- Spahn-Langguth H, Benet LZ. (1992). Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5–48.
- Treiber A, Miraval T, Bolli MH, et al. (2016). The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog. Xenobiotica 46:253–67.
- Uetrecht J. (2001). Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel 4:55–9.
- Uetrecht J, Naisbitt DJ. (2013). Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 65:779–808.
- Volland C, Sun H, Dammeyer J, Benet LZ. (1991). Stereoselective degradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to plasma protein. Drug Metab Dispos 19:1080–6.
- Zia-Amirhosseini P, Harris RZ, Brodsky FM, Benet LZ. (1995). Hypersensitivity to nonsteroidal anti-inflammatory drugs. Nat Med 1:2–4.